Grandeur Peak Global Advisors LLC Sells 19,657 Shares of Stevanato Group S.p.A. (NYSE:STVN)

Grandeur Peak Global Advisors LLC trimmed its stake in shares of Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 2.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 779,537 shares of the company's stock after selling 19,657 shares during the period. Stevanato Group comprises about 1.5% of Grandeur Peak Global Advisors LLC's portfolio, making the stock its 15th largest position. Grandeur Peak Global Advisors LLC owned about 0.26% of Stevanato Group worth $16,986,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. Van Berkom & Associates Inc. bought a new position in shares of Stevanato Group during the fourth quarter worth about $39,000. Wells Fargo & Company MN grew its stake in shares of Stevanato Group by 680.3% during the 4th quarter. Wells Fargo & Company MN now owns 3,246 shares of the company's stock worth $71,000 after acquiring an additional 2,830 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Stevanato Group by 1,457.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company's stock valued at $123,000 after purchasing an additional 5,291 shares during the last quarter. US Bancorp DE lifted its position in shares of Stevanato Group by 17.9% in the fourth quarter. US Bancorp DE now owns 8,527 shares of the company's stock worth $186,000 after purchasing an additional 1,295 shares in the last quarter. Finally, Marco Investment Management LLC acquired a new position in Stevanato Group during the fourth quarter worth $203,000.

Stevanato Group Stock Performance

Shares of NYSE STVN traded down €0.35 ($0.40) during trading hours on Thursday, reaching €21.73 ($24.69). 242,901 shares of the stock were exchanged, compared to its average volume of 351,305. The firm has a market capitalization of $6.58 billion, a price-to-earnings ratio of 46.23, a P/E/G ratio of 7.18 and a beta of 0.52. The stock's fifty day simple moving average is €20.51 and its 200 day simple moving average is €20.66. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81. Stevanato Group S.p.A. has a 52 week low of €16.56 ($18.82) and a 52 week high of €29.11 ($33.08).

Stevanato Group (NYSE:STVN - Get Free Report) last announced its earnings results on Thursday, March 6th. The company reported €0.20 ($0.23) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of €0.20 ($0.23). The company had revenue of €352.68 million during the quarter, compared to analysts' expectations of €346.26 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. Sell-side analysts predict that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on STVN. William Blair reissued an "outperform" rating on shares of Stevanato Group in a research report on Friday, March 7th. UBS Group reduced their price target on Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a research report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Stevanato Group presently has an average rating of "Moderate Buy" and an average price target of €25.70 ($29.20).

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.